GT Biopharma Inc. held its annual meeting of stockholders on July 24, 2025. During the meeting, four members were elected to the Board of Directors, including Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. The appointment of Weinberg & Company, P.A. as independent accountants for the year ending December 31, 2025, was ratified. The amendment to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan, increasing the number of shares available for future awards by 583,334 shares of Common Stock, was approved. The issuance of 19.99% or more of the outstanding shares of Common Stock, as outlined in the Securities Purchase Agreement and the Common Shares Purchase Agreement, was also approved.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。